Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerd Sutter

Showing results (71-80 of 179) with videos related to

Pageof 18
Sort By:
Vaccine|July 28, 2018
N-terminal domain of Schmallenberg virus envelope protein Gc delivered by recombinant equine herpesvirus type 1 and modified vaccinia virus Ankara: Immunogenicity and protective efficacy in cattleKerstin Wernike, Alice Mundt, Ellen Kathrin Link, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 31, 2014
Complement component C5 recruits neutrophils in the absence of C3 during respiratory infection with modified vaccinia virus AnkaraPhilip J R Price, Zoltán Bánki, Angelika Scheideler, et al.
Vaccine|November 29, 2024
A Brighton collaboration standardized template with key considerations for a benefit/risk assessment for a viral vector vaccine based on a non-replicating modified vaccinia virus Ankara viral vectorEllen K Link, Alina Tscherne, Gerd Sutter, et al.
International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group|January 13, 2012
Modified vaccinia virus Ankara delivers a robust surrogate marker for immune monitoring to sarcoma cells even if cells are being exposed to chemotherapy and heat treatmentKatharina Tschoep-Lechner, Ingo Drexler, Doreen Hammer, et al.
Cancer Gene Therapy|April 4, 2023
Improving poxvirus-mediated antitumor immune responses by deleting viral cGAMP-specific nucleaseStephanie Riederer, Ana Del Canizo, Javier Navas, et al.
Journal of Virological Methods|November 29, 2008
Marker gene swapping facilitates recombinant Modified Vaccinia Virus Ankara production by host-range selectionGiulia Di Lullo, Elisa Soprana, Maddalena Panigada, et al.
Vaccine|August 19, 2017
A synthetic human cytomegalovirus pp65-IE1 fusion antigen efficiently induces and expands virus specific T cellsEllen K Link, Christine Brandmüller, Yasemin Suezer, et al.
Frontiers in Cellular and Infection Microbiology|October 19, 2023
The effect of Toll-like receptor agonists on the immunogenicity of MVA-SARS-2-S vaccine after intranasal administration in miceKim Thi Hoang Do, Stefanie Willenzon, Jasmin Ristenpart, et al.
Vaccine|November 8, 2003
Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individualsAntonio Cosma, Rashmi Nagaraj, Silja Bühler, et al.
Cytotherapy|January 22, 2011
Uptake of antigens from modified vaccinia Ankara virus-infected leukocytes enhances the immunostimulatory capacity of dendritic cellsChristin Flechsig, Yasemin Suezer, Markus Kapp, et al.
Pageof 18

Showing results (71-80 of 179) with videos related to

Sort By:
Pageof 18
Vaccine|July 28, 2018
N-terminal domain of Schmallenberg virus envelope protein Gc delivered by recombinant equine herpesvirus type 1 and modified vaccinia virus Ankara: Immunogenicity and protective efficacy in cattleKerstin Wernike, Alice Mundt, Ellen Kathrin Link, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 31, 2014
Complement component C5 recruits neutrophils in the absence of C3 during respiratory infection with modified vaccinia virus AnkaraPhilip J R Price, Zoltán Bánki, Angelika Scheideler, et al.
Vaccine|November 29, 2024
A Brighton collaboration standardized template with key considerations for a benefit/risk assessment for a viral vector vaccine based on a non-replicating modified vaccinia virus Ankara viral vectorEllen K Link, Alina Tscherne, Gerd Sutter, et al.
International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group|January 13, 2012
Modified vaccinia virus Ankara delivers a robust surrogate marker for immune monitoring to sarcoma cells even if cells are being exposed to chemotherapy and heat treatmentKatharina Tschoep-Lechner, Ingo Drexler, Doreen Hammer, et al.
Cancer Gene Therapy|April 4, 2023
Improving poxvirus-mediated antitumor immune responses by deleting viral cGAMP-specific nucleaseStephanie Riederer, Ana Del Canizo, Javier Navas, et al.
Journal of Virological Methods|November 29, 2008
Marker gene swapping facilitates recombinant Modified Vaccinia Virus Ankara production by host-range selectionGiulia Di Lullo, Elisa Soprana, Maddalena Panigada, et al.
Vaccine|August 19, 2017
A synthetic human cytomegalovirus pp65-IE1 fusion antigen efficiently induces and expands virus specific T cellsEllen K Link, Christine Brandmüller, Yasemin Suezer, et al.
Frontiers in Cellular and Infection Microbiology|October 19, 2023
The effect of Toll-like receptor agonists on the immunogenicity of MVA-SARS-2-S vaccine after intranasal administration in miceKim Thi Hoang Do, Stefanie Willenzon, Jasmin Ristenpart, et al.
Vaccine|November 8, 2003
Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individualsAntonio Cosma, Rashmi Nagaraj, Silja Bühler, et al.
Cytotherapy|January 22, 2011
Uptake of antigens from modified vaccinia Ankara virus-infected leukocytes enhances the immunostimulatory capacity of dendritic cellsChristin Flechsig, Yasemin Suezer, Markus Kapp, et al.
Pageof 18